89
Participants
Start Date
June 7, 2018
Primary Completion Date
August 31, 2023
Study Completion Date
November 30, 2023
Pexastimogene Devacirepvec (Pexa-Vec)
Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
Cemiplimab
Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
Site 2620 Seoul National University Bundang Hospital, Seongnam-si
Site 2623 Ajou University Hospital, Suwon
Site 2641 University of Miami, Miami
Site 2616 Chungnam National University Hospital, Daejeon
Site 2617 CHA University, CHA Bundang Medical Center, Seongnam
Site 2612 Kyungpook National University Chilgok Hospital, Daegu
Site 2646 The Ohio State University, Columbus
Site 2613 Dong-A University Hospital, Pusan
Site 2619 Pusan National University Hospital, Pusan
Site 2625 Wonju Severance Christian Hospital, Wŏnju
Site 2624 Pusan National University Yangsan Hospital, Yangsan
Site 2618 Chonnam National University Hwasun Hospital, Gwangju
Site 2643 Washington University, St Louis
Site 2644 University of California, Irvine, Irvine
Site 2632 Flinders Medical Centre, Bedford Park
Site 2622 Gachon University Gil Medical Center, Incheon
Site 2615 Korea University Anam Hospital, Seoul
Site 2610 Severance Hospital, Yonsei University Health System, Seoul
Regeneron Pharmaceuticals
INDUSTRY
SillaJen, Inc.
INDUSTRY